Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Altasciences Contributes to Vibegron Approval | Contract Pharma

What are you searching for?

Sign in
Breaking News

Altasciences Contributes to Vibegron Approval

Provided clinical support for two drug-drug interaction studies and a bioavailability trial for the overactive bladder treatment.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Altasciences has contributed to the recent FDA approval of Vibegron, a beta-3 adrenergic receptor (β3) agonist for the treatment of overactive bladder, conducting multiple early phase clinical trialsfor Urovant Sciences.
 
Altasciences provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects. These trials were supported by Altasciences’ data services team, who performed the full data management and reporting for the associated clinical studies.  
 
“We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of patients,” said Amy Denvir, General Manager at Altasciences’ Kansas clinical pharmacology unit. “Working with Urovant Sciences on this program has been a pleasure, and we are delighted to see it come to fruition.” 
 
Altasciences is a mid-size contract research organization offering preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics